Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Universal BCMA-targeted LUCAR-B68 Cells Product in Patients With Relapsed/Refractory Multiple Myeloma

NCT05498545 is registered in ClinicalTrials.gov with Second Affiliated Hospital of Xi'an Jiaotong University as lead sponsor.

NCT NCT05498545
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05498545 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of Universal BCMA-targeted LUCAR-B68 Cells Product in Patients With Relapsed/Refractory Multiple Myeloma
Lead sponsor
Second Affiliated Hospital of Xi'an Jiaotong University
Phase
Phase 1
Overall status
Terminated
Start date
November 24, 2022
Completion date
May 30, 2025
Enrollment
8 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory multiple myeloma